title: Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis.
abstract: BACKGROUND
  Prednisone and methylprednisolone are well absorbed orally and have lower treatment costs than IV methylprednisolone, but concern that low-dose corticosteroid may cause increased disease activity and that high oral doses may cause gastric ulceration inhibits use of oral therapy for MS attacks.
  
  
  METHODS
  Gastric mucosal injury, detected by measurement of gastric permeability, was examined after five alternate day doses of IV methylprednisolone (1 g) or oral prednisone (1,250 mg) in 21 patients with MS. A triple sugar test solution was consumed at bedtime, and urine was collected overnight. Urine sugar concentrations were determined by high-pressure liquid chromatography. Gastric permeability was expressed as total mg of sucrose excreted.
  
  
  RESULTS
  Seventeen patients completed the protocol (12 oral, 5 IV). Baseline sucrose excretion was normal in all. Both groups demonstrated an increase in gastric permeability after steroid treatment, but there was no difference between the two groups (95% CI 95 to 91 mg, p = 0.96). After treatment, three (25%) patients in the oral group, and two (40%) patients the IV group, had modestly abnormal gastric permeability (95% CI 34 to 64%, P = 0.6).
  
  
  CONCLUSIONS
  Short-term high-dose oral prednisone is not associated with greater gastric damage, as measured with permeability tests, than IV methylprednisolone. High-dose oral prednisone should be considered a first-line treatment option for MS attacks.
authors.affiliation: Department of Clinical Neurosciences, University of Calgary, Alberta, Canada.
authors.forename: L M
authors.initials: LM
authors.lastname: Metz
authors.forename: D
authors.initials: D
authors.lastname: Sabuda
authors.forename: R J
authors.initials: RJ
authors.lastname: Hilsden
authors.forename: R
authors.initials: R
authors.lastname: Enns
authors.forename: J B
authors.initials: JB
authors.lastname: Meddings
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000191:economics; D002463:Cell Membrane Permeability / Q000187:drug effects; D003362:Cost-Benefit Analysis; D004305:Dose-Response Relationship, Drug; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000191:economics; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects* / Q000191:economics; D020551:Pulse Therapy, Drug; D013276:Stomach Ulcer / Q000139:chemically induced* / Q000191:economics
chemical_list: D000893:Anti-Inflammatory Agents; D011241:Prednisone